Limited Submissions Opportunities

Information Webinar for Pew Scholars Program and Pew-Stewart Scholars
Tuesday, January 15, 2019 at 2:00 p.m. ET

The Pew Scholars Program and Pew-Stewart Scholars for Cancer Research are national funding initiatives designed to support assistant professors of outstanding promise in science relevant to the advancement of human health. Each award provides $300,000 in flexible support—$75,000 per year for a four-year period.

This year, Pew Biomedical Programs staff will host an informational webinar for institutional nomination committees and potential applicants from the list of participating  institutions for each program so that they may learn more about both programs in advance of our summer 2019 call for nominations. We highly encourage you to register for this event, even if your institution has nominated a candidate in the past. Topics covered will include:

  • Overview of the Pew Charitable Trusts Mission and Current Work
  • Biomedical Funding Opportunities
  • Program Eligibility Criteria for both the Pew Scholars and Pew-Stewart Programs
  • Similarities and differences between the Scholars and Pew-Stewart programs
  • Keys to Selecting a Competitive Candidate
  • Application Process Overview and Timeline

There will also be a Q&A session for clarification of any additional questions you may have.

The webinar will take place on Tuesday, January 15, 2019 at 2:00 p.m. ET. In order to join the program, please fill out this registration form.

NIH Research Evaluation and Commercialization Hub (REACH) Awards
Deadline: January 23, 2019

This FOA announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof of concept work and the mentorship in product development and commercialization needed to develop high priority technologies that address the highest US disease burden within the NIH’s mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship.  Establishing public-private partnerships and providing additional non-federal funds will be critical for success.

Internal applications for the NIH Research Evaluation and Commercialization Hub (REACH) Awards are available on InfoReady. Investigators interested in applying must submit a 1.5 page abstract and cv.

2019 Ono Initiative LOI
Deadline: January 25, 2019

The Ono Pharma Foundation was established to support academic research in relevant scientific fields, which have the potential of making significant impact on therapeutic approaches to disease and pain management.  The Foundation’s competitive awards program, the Ono Pharma Breakthrough Science Initiative Awards Program (“Ono Initiative”), is the embodiment of the Foundation’s commitment to focus on and accelerate researcher-driven open innovation by supporting high-risk and high-reward science research projects which have potential to lead to science discoveries/solutions and, possibly, based on further research, to breakthrough treatments for patients.

 Eligibility Requirements:

Applicants must meet the following requirements. LOIs and final Proposals from applicants not meeting the requirements listed below will not be considered.

  1. Each PI applying chemical biology area must be working in one of the nominating institutions. Nominating institutions might be replaced or added to in subsequent years.
  2. Each PI applying oligonucleotide medicine research area must be working in the United States or Canada.
  3. The PI must have a MD and/or a PhD degree.
  4. The PI may not already be engaged in other sponsored research with Ono Pharmaceutical Co., Ltd. and/or grant program with Ono Pharma Foundation.
  5. The PI may not apply for funding to amplify current work. However, PIs may research a new idea based on a prior findings of the PI.

As a US private foundation, Ono Pharma Foundation grants to Canadian institutions are conditioned on an equivalency determination by the Foundation. This may require additional documentation and information from the institution outside of the application process.

Applications for the 2018 Ono Initiative are available on InfoReady. This is a limited submission that allows 2 nominations from the University of Utah.

Subscribe to the VPR for Research News E-mail ListSubscribe to the VPR for Research News E-mail List